MedPath

Continuous glucose monitoring versus self-monitoring of blood glucose in women with gestational diabetes mellitus

Completed
Conditions
diabetes in pregnancy
Gestational diabetes
10012653
10026908
Registration Number
NL-OMON42812
Lead Sponsor
Maasstadziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
31
Inclusion Criteria

Women who are >=18 years old, diagnosed with GDM, < 36 weeks of gestation, are able to communicate and read in Dutch.

Exclusion Criteria

no singleton pregnancy judged by ultrasonography, diagnosis of diabetes mellitus before the current pregnancy.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary objective: To assess the hyperglycemic episodes (fasting glucose >= 5.3<br /><br>mmol/L and 6.7 mmol/l the rest of the day) detected by the CGMS when the SMBG<br /><br>is normal in a 24 hour period. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>1. The secondary endpoint is mean total time of hyperglycemia (glucose>= 5.3<br /><br>mmol/L fasting and >= 6.7 mmol/L) defined in minutes/day, that is detected by<br /><br>the CGMS compared to standard SMBG (7 measurements in a day).<br /><br><br /><br>2. Is there a difference in glycaemic control (data is binary: hyperglycaemia<br /><br>or no hyperglycaemia) between day 2 (SMBG) and day 3 (no SMBG) of the<br /><br>monitoring period?<br /><br><br /><br>Background (2): We are curious what the effect of SMBG is on the glucose<br /><br>regulation. Is it so that on the day of the SMBG, women adhere better to the<br /><br>diet and on the other days less or not? Possibly suggesting that hyperglycaemia<br /><br>could prevail unnoticed. </p><br>
© Copyright 2025. All Rights Reserved by MedPath